1、TolrestatCat. No.: HY-16500CAS No.: 82964-04-3Molecular Formula: CHFNOSMolecular Weight: 357.35Target: Aldose ReductasePathway: Metabolic Enzyme/ProteaseStorage: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 monthSolvent the lenses and sciatic nerves are removed and homogenized in 5% t
2、richloroacetic acid; the deproteinized extracts are then analyzed for galactitol by a modification of a method for glycerol determination. The values obtained in the group fed 20% glucose are used for background correction.MCE has not independently confirmed the accuracy of these methods. They are f
3、or reference only.REFERENCES1. Sestanj K, et al. N-5-(trifluoromethyl)-6-methoxy-1-naphthalenylthioxomethyl- N-methylglycine (Tolrestat), a potent, orally active aldose reductase inhibitor. J Med Chem. 1984 Mar;27(3):255-6.2. Simard-Duquesne N, et al. The effects of a new aldose reductase inhibitor
4、(tolrestat) in galactosemic and diabetic rats. Metabolism. 1985 Oct;34(10):885-92.3. Srivastava S, et al. Aldose reductase protects against early atherosclerotic lesion formation in apolipoprotein E-null mice. Circ Res. 2009 Oct 9;105(8):793-802.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: techMedChemEAddress: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USAwww.MedChemE2
个人主页
